Welcome to Broadline Capital
Founded 17 years ago, Broadline Capital is a global alternative investment firm focused primarily on growth capital and sustainable investments in North America and Asia. At Broadline, we're inspired by champions — people of vision and courage — whose ideas can positively change the world, and who are ready to transform their ideas into the next industry-changing company.
When evaluating opportunities, we seek companies that are positioned to thrive as the world continues to transition toward an economy increasingly driven by healthy living and the pursuit of a more efficient and sustainable way of life. We seek category leaders and category creators that are reshaping their industry, and prefer highly-charged sectors where innovation, growth, strong margins, and market consolidation are creating abundant opportunities.
We place emphasis on identifying credible management teams who demonstrate the capability to benefit from our established platform, access to industry expertise, and vast network of relationships built over many years. Broadline's transaction leaders and venture partners have spent their entire careers building trust-based relationships globally. They have led some of the most creative deals in their market categories. Their collective experience and relationships combine to support Broadline-sponsored companies to develop to the next level. We believe Broadline’s current opportunities are among the most exciting on the planet.
New York | Miami | Columbus | Seoul | Shanghai
Broadline Capital's proprietary investment process is designed to stretch alpha at every link of the investment value chain. Our past success stems from our highly-replicable methodology based on our multi-source origination process, creative deal structuring, and mitigation through diversification and alignment.
Multi-source origination: Broadline's multi-source origination continuously generates a curated pipeline of privileged-access deals developed from our principals' and venture partners' vast network of relationships built over many years within their areas of focus.
Negotiated deals with tailored structuring and active support: We seek to capture outsized returns by investing in negotiated deals, not auctions. Our transaction is tailored to the unique situation of each company.
Diversification and alignment: We seek less-correlated investment risk by pursuing diversification across a range of industries, geographies, deal structures, development stages, and market capitalizations.
When selecting opportunities, Broadline takes a two-pronged approach:
First, we start with a "Top-Down" view to identify exciting categories that are positioned to grow profitably and create broad impact as the world continues to transition toward an economy increasingly driven by healthy living and the pursuit of a more efficient and sustainable way of life.
Next, we take a "Bottom-Up" view, screening for category creators or category leaders that are helping to reshape these industries, and whose founding management teams display the credibility and readiness to benefit from our support beyond capital.
Targeted Deal Types
We primarily focus on financing a private company's accelerated expansion, product commercialization, or consolidation with compatible enterprises. We place emphasis on promising new business models, rising category creators or category leaders, and innovators of leapfrog technologies that are creating positive impact in targeted areas. Broadline Capital's investment history has enabled our firm to develop and access distinctive capabilities in the following core thematic areas:
Sustainability & Environment
Electrification and Energy Storage (including electric powertrains, lithium-ion battery systems, carbon nanotubes, and OEMs in the value chains for electrified industrial equipment and electric vehicles)
Life Sciences (including new platforms of molecular biotechnology, non-invasive medical devices, and pharmaceuticals for improving patient outcomes)
The Food System
Agribusiness and Consumer Packaged Goods (including non-GMO row cropping, food and beverage manufacturing, and retail delivery)
The Pursuit of a More Efficient Way of Life
Purpose-driven Technology (including creative business models and innovations using SaaS, AI, IoT, Blockchain, Memory and Data Storage)
Financial Services and Fintech (including Insurtech, Payments, Affordable Credit, and Crypto Exchanges)
We invite you to scroll through case examples of portfolio companies below. If you are a current Broadline registered investor, please click on the "Investor Login" tab at the top of this website for management updates and reports from companies in your investment portfolio, and to review our current pipeline of investment opportunities.
Non-INVASIVE Medical Devices
Founded in 2006, EndoSphere is a medical technology company that has developed a first-in-class, non-invasive medical device platform to treat metabolic diseases, including some of the world's largest healthcare issues such as Obesity, Type 2 Diabetes, and Fatty Liver Disease. EndoSphere's novel "Endo-Metabolic" device platform represents a completely new category of devices that uniquely focus on the Duodenum, the upper intestinal organ that is widely recognized as the body's metabolic control center. Endosphere's flagship anti-obesity device is incisionless, reversible and repeatable. In clinical studies, this first device has enabled Obese patients to achieve significant Excess Weight Loss (EWL) without the need for invasive alternatives such as restrictive devices or bariatric surgeries. Unlike restrictive devices and surgeries, which work against nature, EndoSphere's "Endo-Metabolic" devices work with the body, amplifying the natural physiological responses to food intake in order to help accelerate satiety, recalibrate brain-gut metabolic feedback loops, recalibrate hormones, and rebalance insulin levels. EndoSphere's portfolio of patent assets is 100% company-owned and free from any third-party licensing or royalty obligations. EndoSphere has received numerous industry recognitions, including the medical device industry's inaugural "Fierce15" award, named by FierceBiotech, annually recognizing the world's most promising privately-held medical innovations. EndoSphere's first version of its anti-obesity device has received CE Mark (regulatory approval in 31 countries), and its enhanced version has now entered clinical stages of development.
For more information, please visit https://www.EndoSphereInc.com.
Sustainability & Environment
Founded in 2010, Powermers has developed the world's first Carbon-Free Lithium-ion Batteries by replacing "deadweight" materials in conventional cathodes (carbon and binders) with Powermers' proprietary conductive nano-scale advanced materials. Powermers' transition-metal polymers demonstrate higher catalytic functionality than the pure noble-metal catalysts of gold, platinum, and palladium. The result: measurably safer and higher-performing lithium-ion batteries, independently-validated by the industry's recognized third-party battery testing labs including the US Army Corps of Engineers' battery innovation lab ("CERL") and The Ohio State University's Center for Automotive Research lab ("OSU CAR"). These independently-validated performance and safety results of Powermers' Carbon-free Lithium-ion Battery Technology were published by the peer-reviewed journal, American Chemical Society (ACS) Applied Materials & Interfaces Journal. Powermers owns 100% of its IP asset portfolio, free from any third-party licensing or royalty obligations. Lithium-ion batteries using Powermers' carbon-replacement technology have demonstrated the following key sources of differentiation:
Better Safety and Stability: Powermers' technology significantly improves safety and stability for high-voltage lithium-ion batteries by reducing the Thermal Runaway Risk, which is a primary cause of high-voltage lithium-ion battery over-heating. In past years, Thermal Runaway Risk caused billions of dollars in market value losses in high-profile situations experienced by Tesla and Samsung, whose customers place a high priority on product safety.
Higher Performance: Replacing conventional "deadweight" components of carbon and binders with our conductive polymers helps to expand the resulting battery's Active Material Limit, increasing its Specific Energy without sacrificing any other KPI including Power, Cycle Life, Weight, or Cost per KWH.
Cost Efficiencies and Ease of Adoption: Powermers' carbon-replacement technology can be readily adopted by battery manufacturers because it does not require a significant change to the established steps in a facility's manufacturing process. It also enables total cost savings per KWH because of the reduced need for solvents and other efficiency benefits.
For more information, please visit https://www.Powermers.com.
Broadline Capital's transaction leaders and venture partners are past CEOs and entrepreneurs who have previously founded and led successful companies where they created significant value and negotiated quality exits for themselves and their investors. They have spent their entire careers building trust-based relationships globally, and have led some of the most creative deals in the history of their respective categories. They understand what it takes to build a business, how to take a private company public, and how to align varied stakeholders, because they've been there.
Staying close to their roots as innovators and company operators, our transaction leaders and venture partners love collaborating with an inspired management team to build something special as they work together toward realizing the shared vision for the company.
"At Broadline Capital, we are inspired by champions – people of vision and courage – whose ideas can positively change the world, and who are ready to transform their ideas into the next industry-changing company. If you share our perspective, we invite you to join us. We look forward to hearing from you."
MIAMI: Brickell City Tower, 80 SW 8th St., 20th Floor, Miami, FL 33130
MANHATTAN: 1 Rockefeller Plaza, 11th Floor, New York, NY 10020
Broadline ® is a Registered Trademark.
Copyright © Broadline Capital 2004-2021
All Rights Reserved.